NEW YORK, October 28, 2016 /PRNewswire/ --
Stock-Callers.com has issued research reports on these four Generic Drugsequities: Zoetis Inc. (NYSE: ZTS), Sophiris Bio Inc. (NASDAQ: SPHS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Mallinckrodt PLC (NYSE: MNK). According to the report by Research and Markets, the global industry is forecast to grow at a CAGR of 10.53%
At the close on Thursday, shares in Florham Park, New Jersey headquartered Zoetis Inc. ended the day flat at $48.77. The stock recorded a trading volume of 2.56 million shares. The Company's shares have advanced 2.42% since the start of this year. The stock is trading above its 200-day moving average by 3.43%. Moreover, shares of Zoetis, which engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals in the US and internationally, have a Relative Strength Index (RSI) of 34.61.
On October 06th, 2016, The Board of Directors of Zoetis declared Q4 2016 dividend payable to holders of its common stock of $0.095 per share. The dividend is to be paid on December 1st, 2016, to holders of record on November 3rd, 2016.
On September 29th, 2016, research firm Bank of America/ Merrill resumed its 'Buy' rating on the Company's stock. ZTS complete research report is just a click away and free at:
Shares in La Jolla, California-based Sophiris Bio Inc. ended the day 5.02% lower at $2.84 and with a total trading volume of 678,308 shares. The stock has gained 59.55% on an YTD basis. The Company's shares are trading above their 200-day moving average by 18.64%. Furthermore, shares of Sophiris Bio, which focuses on the development of products for the treatment of urological diseases, have an RSI of 41.16. The complimentary report on SPHS can be downloaded at:
On Thursday, shares in California-based Rigel Pharmaceuticals Inc. finished 1.16% lower at $2.55 with a total trading volume of 1.55 million shares. The stock has advanced 11.35% over the previous three months. The Company's shares are trading below their 200-day moving average by 4.56%. Additionally, shares of Rigel Pharmaceuticals, which engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 23.39.
On October 20th, 2016, Rigel Pharmaceuticals announced results for the second of two double-blind studies in the FIT Phase 3 clinical program for fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in adult chronic/persistent immune thrombocytopenia (ITP). In the FIT 2 (Study 048) Phase 3 study, the fostamatinib response rate was 18%, consistent with the recently reported FIT 1 (Study 047) Phase 3 study. In Study 048, one patient in the placebo group (4%) achieved a stable platelet response; therefore the difference between those on treatment and those on placebo did not reach statistical significance (p=0.152) and the study did not meet its primary endpoint. When the data from both studies are combined, however, this difference is statistically significant (p=0.007). Sign up for your complimentary research report on RIGL at:
The UK-based Mallinckrodt PLC's shares recorded a trading volume of 803,746 shares at the end of yesterday's session and closed the day at $63.04, gaining 0.27%. The stock is trading below its 200-day moving average by 4.19%. Shares of the Company, which develops, manufactures, markets, and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents in the US, Europe, the Middle East, Africa, and internationally, have an RSI of 33.03.
On September 29th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $91 a share to $89 a share.
As per notes filed with the SEC on October 24th, 2016, the US Court of Appeals for the Fourth Circuit issued an Order on October 21st, 2016, removing Mallinckrodt Inc.'s pending litigation with the U.S. Food and Drug Administration (FDA) from the Court's oral argument calendar and placing that litigation in abeyance pending the outcome of the Approval Withdrawal Proceedings initiated by the FDA on October 17th, 2016. In response, on October 21st, 2016, Mallinckrodt filed a Motion to Reconsider with the Court requesting that the oral arguments be placed back on the Court's calendar and that the litigation be allowed to proceed. On October 24, 2016, the Court affirmed its earlier decision. The company has stated that its generic methylphenidate ER product is a safe and effective treatment option for patients who suffer from ADHD. As such, Mallinckrodt plans to set forth its position in the Approval Withdrawal Proceedings. Get free access to your research report on MNK at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!